{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T19:23:00Z","timestamp":1765826580756,"version":"3.48.0"},"reference-count":39,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T00:00:00Z","timestamp":1686268800000},"content-version":"unspecified","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019854","name":"Copenhagen Health Science Partners","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100019854","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100012774","name":"Innovationsfonden","doi-asserted-by":"publisher","award":["0176-00020B"],"award-info":[{"award-number":["0176-00020B"]}],"id":[{"id":"10.13039\/100012774","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2023,4,27]]},"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Febrile urinary tract infection is one of the most common bacterial infections in children. Currently, recommended antibiotic duration is 10 days. However, recent evidence suggests that 90%\u201395% of children with febrile urinary tract infections are afebrile and clinically improved 48\u201372\u2009hours after treatment initiation. Accordingly, individualised duration of antibiotic therapy, according to the recovery time, might be more beneficial than current recommendations, but no evidence exists.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>An open-label randomised clinical trial equally randomising children aged 3 months to 12 years from eight Danish paediatric departments with uncomplicated febrile (\u226538\u00b0C) urinary tract infection to either individualised or standard duration of antibiotic therapy. Children allocated to individualised duration of antibiotic therapy will terminate antibiotic therapy 3\u2009days after clinical improvement with no fever, flank pain or dysuria. Children allocated to standard duration will receive 10 days of antibiotic therapy. Co-primary outcomes are non-inferiority for recurrent urinary tract infection or death within 28 days after the end of treatment (non-inferiority margin 7.5\u2009percentage points) and superiority for the number of days with antibiotic therapy within 28 days after treatment initiation. Seven other outcomes will also be assessed. A total of 408 participants are needed to detect non-inferiority (one-sided alpha 2.5%; beta 80%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>This trial has been approved by the Ethics Committee (H-21057310) and the Data Protection Agency (P-2022-68) in Denmark. Regardless of the trial\u2019s findings (whether positive, negative or inconclusive), the results will be compiled into one or more manuscripts for publication in international peer-reviewed scientific journals and presented at conferences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05301023\">NCT05301023<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2022-070888","type":"journal-article","created":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T10:13:02Z","timestamp":1686305582000},"page":"e070888","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Individualised versus standard duration of antibiotic therapy in children with acute uncomplicated febrile urinary tract infection: a study protocol and statistical analysis plan for a multicentre randomised clinical trial"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct05301023","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05301023","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05301023","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01595529","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01595529","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04400110","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04400110","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8025-1939","authenticated-orcid":false,"given":"Naqash","family":"Sethi","sequence":"first","affiliation":[{"name":"Department of Pediatrics and Adolescent Medicine, Rigshospitalet, Copenhagen, Denmark"},{"name":"Department of Pediatrics and Adolescent Medicine, Hvidovre Hospital, Hvidovre, Denmark"},{"name":"Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma Louise Malchau","family":"Carlsen","sequence":"additional","affiliation":[{"name":"Department of Neonatology, Rigshospitalet, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ida Maria","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Adolescent Medicine, Rigshospitalet, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dina","family":"Cortes","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Adolescent Medicine, Hvidovre Hospital, Hvidovre, Denmark"},{"name":"Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrikka","family":"Nygaard","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Adolescent Medicine, Rigshospitalet, Copenhagen, Denmark"},{"name":"Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Line Thousig","family":"Sehested","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Adolescent Medicine, Rigshospitalet, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,6,9]]},"reference":[{"key":"2025121511191554000_13.6.e070888.1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e31815e4122"},{"key":"2025121511191554000_13.6.e070888.2","doi-asserted-by":"crossref","first-page":"721","DOI":"10.3109\/23744235.2016.1168937","article-title":"Best oral empirical treatment for pyelonephritis in children: do we need to differentiate between age and gender?","volume":"48","author":"Salomonsson","year":"2016","journal-title":"Infectious Diseases"},{"key":"2025121511191554000_13.6.e070888.3","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3345\/cep.2020.00773","article-title":"Febrile urinary tract infection in children: changes in epidemiology, etiology, and antibiotic resistance patterns over a decade","volume":"64","author":"Suh","year":"2021","journal-title":"Clin Exp Pediatr"},{"key":"2025121511191554000_13.6.e070888.4","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.159.10.924"},{"key":"2025121511191554000_13.6.e070888.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.01.069"},{"key":"2025121511191554000_13.6.e070888.6","doi-asserted-by":"crossref","unstructured":"Subcommittee on Urinary Tract Infection, Roberts KB , Downs SM , et al . Reaffirmation of AAP clinical practice guideline: the diagnosis and management of the initial urinary tract infection in febrile infants and young children 2\u201324 months of age. Pediatrics 2016;138. doi:10.1542\/peds.2016-3026","DOI":"10.1542\/peds.2016-3026"},{"key":"2025121511191554000_13.6.e070888.7","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/pch\/19.6.315","article-title":"Urinary tract infections in infants and children: diagnosis and management","volume":"19","author":"Robinson","year":"2014","journal-title":"Paediatr Child Health"},{"key":"2025121511191554000_13.6.e070888.8","doi-asserted-by":"publisher","DOI":"10.1111\/apa.14988"},{"key":"2025121511191554000_13.6.e070888.9","doi-asserted-by":"crossref","unstructured":"Strohmeier Y , Hodson EM , Willis NS , et al . Antibiotics for acute pyelonephritis in children. Cochrane Database Syst Rev 2014:CD003772. doi:10.1002\/14651858.CD003772.pub4","DOI":"10.1002\/14651858.CD003772.pub4"},{"key":"2025121511191554000_13.6.e070888.10","unstructured":"National Institute for Health and Clinical Excellence . Pyelonephritis (acute): antimicrobial prescribing (NICE guideline 111). 2020. Available: https:\/\/www.nice.org.uk\/guidance\/ng111 [Accessed 25 Jan 2022]."},{"key":"2025121511191554000_13.6.e070888.11","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/S0140-6736(20)30676-0","article-title":"Urinary tract infections in children","volume":"395","author":"Tullus","year":"2020","journal-title":"Lancet"},{"key":"2025121511191554000_13.6.e070888.12","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2017-314576"},{"key":"2025121511191554000_13.6.e070888.13","doi-asserted-by":"crossref","DOI":"10.1542\/peds.105.5.e59","article-title":"Nonresponders: prolonged fever among infants with urinary tract infections","volume":"105","author":"Bachur","year":"2000","journal-title":"Pediatrics"},{"key":"2025121511191554000_13.6.e070888.14","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1001\/jamainternmed.2017.1938","article-title":"Association of adverse events with antibiotic use in hospitalized patients","volume":"177","author":"Tamma","year":"2017","journal-title":"JAMA Intern Med"},{"key":"2025121511191554000_13.6.e070888.15","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1093\/jpids\/piaa173","article-title":"Antibiotic-associated adverse events in hospitalized children","volume":"10","author":"Same","year":"2021","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2025121511191554000_13.6.e070888.16","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2020.1854008"},{"key":"2025121511191554000_13.6.e070888.17","doi-asserted-by":"crossref","first-page":"572912","DOI":"10.3389\/fcimb.2020.572912","article-title":"Antibiotics as major disruptors of gut microbiota","volume":"10","author":"Ramirez","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"key":"2025121511191554000_13.6.e070888.18","doi-asserted-by":"crossref","DOI":"10.3390\/antibiotics10040393","article-title":"Antibiotic resistance in pediatric infections: global emerging threats, predicting the near future","volume":"10","author":"Romandini","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"2025121511191554000_13.6.e070888.19","doi-asserted-by":"publisher","DOI":"10.1177\/2042098614554919"},{"key":"2025121511191554000_13.6.e070888.20","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa439.833","article-title":"639. short course therapy for urinary tract infections (SCOUT) in children","volume":"7","author":"Zaoutis","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2025121511191554000_13.6.e070888.21","unstructured":"ClinicalTrials.gov . The SCOUT study: 'Short course therapy for urinary tract infections in children'. NCT01595529 . n.d. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01595529"},{"key":"2025121511191554000_13.6.e070888.22","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.3951","article-title":"Comparative effectiveness of antibiotic treatment duration in children with pyelonephritis","volume":"3","author":"Fox","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2025121511191554000_13.6.e070888.23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01431-8"},{"key":"2025121511191554000_13.6.e070888.24","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02819-2020","article-title":"The early use of antibiotics for at risk children with influenza-like illness (ARCHIE): a double-blind randomised placebo-controlled trial","volume":"58","author":"Wang","year":"2021","journal-title":"Eur Respir J"},{"key":"2025121511191554000_13.6.e070888.25","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1001\/jamapediatrics.2021.5547","article-title":"Short- vs standard-course outpatient antibiotic therapy for community-acquired pneumonia in children: the SCOUT-CAP randomized clinical trial","volume":"176","author":"Williams","year":"2022","journal-title":"JAMA Pediatr"},{"key":"2025121511191554000_13.6.e070888.26","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.17843"},{"key":"2025121511191554000_13.6.e070888.27","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e3181f55a89"},{"key":"2025121511191554000_13.6.e070888.28","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-019479","article-title":"7-Day compared with 10-day antibiotic treatment for febrile urinary tract infections in children: protocol of a randomised controlled trial","volume":"8","author":"Daniel","year":"2018","journal-title":"BMJ Open"},{"key":"2025121511191554000_13.6.e070888.29","unstructured":"ClinicalTrials.gov . Short therapy for febrile UTI in childhood. NCT04400110 . n.d. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04400110"},{"key":"2025121511191554000_13.6.e070888.30","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.281053"},{"key":"2025121511191554000_13.6.e070888.31","unstructured":"ICH Harmonised Guideline . Integrated addendum to ICH E6 (R1). Guideline for good clinical practice E6 (R2). 2016. Available: https:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E6\/E6_R2__Step_4_2016_1109.pdf"},{"key":"2025121511191554000_13.6.e070888.32","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e7586","article-title":"SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials","volume":"346","author":"Chan","year":"2013","journal-title":"BMJ"},{"key":"2025121511191554000_13.6.e070888.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"2025121511191554000_13.6.e070888.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208"},{"key":"2025121511191554000_13.6.e070888.35","unstructured":"Sehested LT , N\u00f8rgaard H , Hagstr\u00f8m S , et al . Pyelonefritis hos b\u00f8rn og unge [Nefrologiudvalget, Danish Paediatric Society]. 2020. Available: http:\/\/paediatri.dk\/images\/dokumenter\/Retningslinjer_2020\/DPS-Pyelonefrit_2020.pdf"},{"key":"2025121511191554000_13.6.e070888.36","article-title":"Impact of cleaning before obtaining midstream urine samples from children","volume":"61","author":"Lytzen","year":"2014","journal-title":"Dan Med J"},{"key":"2025121511191554000_13.6.e070888.37","first-page":"231","article-title":"International Conference on harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH) adopts consolidated guideline on good clinical practice in the conduct of clinical trials on medicinal products for human use","volume":"48","year":"1997","journal-title":"Int Dig Health Legis"},{"key":"2025121511191554000_13.6.e070888.38","unstructured":"United States Food & Drug Administration . Adaptive designs for clinical trials of drugs and biologics. guidance for industry. 2019. Available: https:\/\/www.fda.gov\/media\/78495\/download"},{"key":"2025121511191554000_13.6.e070888.39","doi-asserted-by":"publisher","DOI":"10.1002\/bimj.200610373"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2022-070888","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T19:19:26Z","timestamp":1765826366000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2022-070888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":39,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6,9]]},"published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1136\/bmjopen-2022-070888"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2022-070888","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2023,6]]}}}